Page 1

Pluristem Therapeutics Inc. (NASDAQ:PSTI)

About Pluristem Therapeutics Inc. (NASDAQ:PSTI) Pluristem Therapeutics Inc. (Pluristem) is a bio-therapeutics company engaged in the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from human placenta, a non-controversial, nonembryonic, adult stromal cell source. The placental adherent stromal cells (ASCs)are grown in the Company's PluriX three-dimensional (3-D) bioreactor, which imitates the natural microstructure of the body. It is focusing on clinical indication that the route of administration is intramuscular. This route of administration applicable for several different indications, such as Peripheral artery disease(PAD), Critical limb ischemia (CLI), intermittent claudication, neuropathic pain, wound healing and orthopedic injuries.

Statistics Symbol


Shares Outstanding


Current Price


Market Capitalization:


52 week range

$0.94 - $4.17



Avg Volume




Financials Pluristem Therapeutics Inc. (NASDAQ:PSTI) engendered net income of negative $1.69 million in current quarter which is slightly greater than previous quarter’s net income of negative $1.74 million. Moreover, net income is negative which led to negative EPSfor the current quarter. The company’s cash flow from operation stood at negative $0.69 million as contrasted to last quarter’s cash flow from operation which was placed at negative $5.41 million. CFOis kept decreasing which is not a good sign and it shows if this trend continuous than company could face some liquidity problems in future. The company’s total assets accumulate up to $4.37 million as per its latest financials as on September 30, 2010. Current assets claim to have the highest contribution in the total assets. Return on equity and return on assets both are decreasing. Total liabilities and total equity stand at $1.63 million and $2.73 million respectively.


We are not registered as a securities broker-dealer or an investment advisor either within the U.S. Securities and Exchange Commission (the “SEC�) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.

The information contained on our website or in any of our newsletters should be viewed as commercial advertisement and is not intended to be investment advice. Any information found on our website, or in any of our newsletters is not provided to any particular individual with a view toward their individual circumstances. The information contained on our website, and in any newsletter we distribute, is not an offer to buy or sell securities. We distribute opinions, comments, and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposesonly and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report. Individuals should assume that all information contained on our website or in one of our newsletters about profiled companies is not trustworthy unless verified by their own independent research.

Any individual who choosesto invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment adviser or licensed stock broker before investing.

This newsletter is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licensesand are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. is a wholly-owned subsidiary of SeoFreisin, Inc.. While SeoFreisin has not been compensated for the distribution of this particular email, any future email regarding a specific company will be the result of an advertising and promotional campaign for which SeoFreisin, Inc. receives compensation. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company.

Becauseof this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. SeoFreisin and its affiliates currently hold no shares in the profiled company.

SeoFreisin, Inc., and/or its affiliates will hold, buy, and sell securities in the companies profiled. When compensated in shares, all readers should be aware that it is our policy to liquidate all shares immediately. We reserve the right to buy or sell the shares of any the companies mentioned in any materials we produce at any time. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled companies.

Information contained in our report will contain “forward looking statements” as defined under section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward looking statements. These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could causeactual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussedin each profiled company’s most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completenessof the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.

To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in this report, or for any direct, indirect, consequential, incidental, special or punitive damagesthat may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss opportunities, trading losses,and damagesthat may result from any inaccuracy or incompletenessof this information).

Pluristem Therapeutics Inc  
Pluristem Therapeutics Inc  

About Pluristem Therapeutics Inc. (NASDAQ:PSTI) Pluristem Therapeutics Inc. (NASDAQ:PSTI) Current Price $3.96 Market Capitalization: 104.23M...